⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNXP News
Tonix Pharmaceuticals Holding Corp.
Form 8-K
sec.gov
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
globenewswire.com
TNXP
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP